Phase 3 Study of Oral KVD900 as On-Demand Therapy Likely in 2022

Phase 3 Study of Oral KVD900 as On-Demand Therapy Likely in 2022

311974

Phase 3 Study of Oral KVD900 as On-Demand Therapy Likely in 2022

KalVista Pharmaceuticals is planning to launch a Phase 3 trial of KVD900, an investigational oral and on-demand treatment for adults with hereditary angioedema (HAE), with dosing expected to begin in early 2022. “Our development team is finalizing the Phase 3 trial protocol and preparing for study initiation, and we anticipate patients will be dosed during the first quarter of 2022,” Andrew Crockett, CEO of KalVista, said in a press release. KVD900 is designed to block…

You must be logged in to read/download the full post.